1. Home
  2. QNBC vs AGEN Comparison

QNBC vs AGEN Comparison

Compare QNBC & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo QNB Corp. Common Stock

QNBC

QNB Corp. Common Stock

N/A

Current Price

$46.12

Market Cap

281.3M

Sector

Finance

ML Signal

N/A

Logo Agenus Inc.

AGEN

Agenus Inc.

SELL

Current Price

$6.70

Market Cap

335.6M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
QNBC
AGEN
Founded
1877
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
281.3M
335.6M
IPO Year
1996
1999

Fundamental Metrics

Financial Performance
Metric
QNBC
AGEN
Price
$46.12
$6.70
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
★ $26.33
AVG Volume (30 Days)
18.7K
★ 1.0M
Earning Date
10-23-2026
11-09-2026
Dividend Yield
★ 3.39%
N/A
EPS Growth
21.15
★ 100.00
EPS
★ 1.32
0.96
Revenue
N/A
★ $42,877,086.00
Revenue This Year
N/A
$9.64
Revenue Next Year
N/A
N/A
P/E Ratio
$34.89
★ $7.27
Revenue Growth
N/A
★ 89.95
52 Week Low
$44.75
$2.71
52 Week High
$46.60
$10.19

Technical Indicators

Market Signals
Indicator
QNBC
AGEN
Relative Strength Index (RSI) 58.88 37.94
Support Level $45.00 $6.51
Resistance Level $46.60 $8.64
Average True Range (ATR) 0.47 0.63
MACD 0.06 -0.25
Stochastic Oscillator 65.63 0.43

Price Performance

Historical Comparison
QNBC
AGEN

About QNBC QNB Corp. Common Stock

QNB Corp is a bank holding company based in the United States. It operates through its wholly-owned subsidiary, which engages in the general commercial banking business and offers a full range of banking services to its customers. Its business activities involve attracting deposits and using funds in making commercial loans, residential mortgage loans, consumer loans, and purchasing investment securities. The loan portfolio includes commercial loans, such as commercial and industrial, construction, and loans secured by commercial real estate and residential real estate, and retail loans, including home equity loans and lines, and consumer loans. It generates revenue from net interest income.

About AGEN Agenus Inc.

Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.

Share on Social Networks: